This is a Validated Antibody Database (VAD) review about mouse Ctla4, based on 98 published articles (read how Labome selects the articles), using Ctla4 antibody in all methods. It is aimed to help Labome visitors find the most suited Ctla4 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Ctla4 synonym: Cd152; Ctla-4; Ly-56

BioLegend
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 2a
BioLegend Ctla4 antibody (BioLegend, 106306) was used in flow cytometry on mouse samples (fig 2a). Sci Adv (2022) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 8b
BioLegend Ctla4 antibody (Biolegend, 106312) was used in flow cytometry on mouse samples (fig 8b). PLoS Pathog (2022) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig s3
BioLegend Ctla4 antibody (BioLegend, 106305) was used in flow cytometry on mouse samples (fig s3). Cell Rep (2022) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; 1:100; loading ...; fig s7f
BioLegend Ctla4 antibody (BioLegend, UC10-4B9) was used in flow cytometry on mouse samples at 1:100 (fig s7f). J Immunother Cancer (2021) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; 1:500; fig s2e
BioLegend Ctla4 antibody (BioLegend, UC10-4B9) was used in flow cytometry on mouse samples at 1:500 (fig s2e). Sci Adv (2021) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...
BioLegend Ctla4 antibody (BioLegend, 106312) was used in flow cytometry on mouse samples . Cell (2020) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 5f
BioLegend Ctla4 antibody (Biolegend, UC10-4B9) was used in flow cytometry on mouse samples (fig 5f). Cell (2020) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig s3a, s3b, s3c, s4a
BioLegend Ctla4 antibody (BioLegend, 106310) was used in flow cytometry on mouse samples (fig s3a, s3b, s3c, s4a). Cancers (Basel) (2020) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 2c
BioLegend Ctla4 antibody (Biolegend, UC10-4B9) was used in flow cytometry on mouse samples (fig 2c). elife (2020) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 2d
BioLegend Ctla4 antibody (Biolegend, 106306) was used in flow cytometry on mouse samples (fig 2d). Cell Rep (2019) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig s4f
BioLegend Ctla4 antibody (Biolegend, 106306) was used in flow cytometry on mouse samples (fig s4f). Cell (2019) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig s5c
BioLegend Ctla4 antibody (Biolegend, UC10-4B9) was used in flow cytometry on mouse samples (fig s5c). J Clin Invest (2019) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...
BioLegend Ctla4 antibody (BioLegend, UC10-4B9) was used in flow cytometry on mouse samples . Nature (2019) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 3e
BioLegend Ctla4 antibody (Biolegend, UC10-4B9) was used in flow cytometry on mouse samples (fig 3e). Science (2019) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig s8b
BioLegend Ctla4 antibody (BioLegend, 106311) was used in flow cytometry on mouse samples (fig s8b). Nat Commun (2019) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig s3
BioLegend Ctla4 antibody (Biolegend, 106313) was used in flow cytometry on mouse samples (fig s3). J Clin Invest (2018) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig s8a
BioLegend Ctla4 antibody (Biolegend, 106309) was used in flow cytometry on mouse samples (fig s8a). J Clin Invest (2018) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 3a
BioLegend Ctla4 antibody (Biolegend, UC10-4B9) was used in flow cytometry on mouse samples (fig 3a). J Immunol (2018) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; 1:100; loading ...; fig 4d
BioLegend Ctla4 antibody (BioLegend, uc10-4B9) was used in flow cytometry on mouse samples at 1:100 (fig 4d). Nat Commun (2017) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; 1:300; loading ...; fig 6g
In order to test if oncolytic poxvirus treatment improves anti-PD-L1 immunotherapy, BioLegend Ctla4 antibody (BioLegend, 106316) was used in flow cytometry on mouse samples at 1:300 (fig 6g). Nat Commun (2017) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 5e
In order to analyze the effects of beta-lactam-plus-macrolide therapy using a lethal pneumococcal pneumonia mouse infection model, BioLegend Ctla4 antibody (BioLegend, UC10-4B9) was used in flow cytometry on mouse samples (fig 5e). Antimicrob Agents Chemother (2016) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 3
In order to study the functions of WASp knock out natural killer cells, BioLegend Ctla4 antibody (Biolegend, UC10-4B9) was used in flow cytometry on mouse samples (fig 3). Sci Rep (2016) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig s2
In order to describe a role for Nbn in skin homeostasis, BioLegend Ctla4 antibody (Biolegend, 106305) was used in flow cytometry on mouse samples (fig s2). Oncotarget (2016) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 6
In order to study the requisite for the function of regulatory T cells known as phosphatase PP2A, BioLegend Ctla4 antibody (Biolegend, UC10-4B9) was used in flow cytometry on mouse samples (fig 6). Nat Immunol (2016) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 3b
In order to study the interactions between hepatoma cells and anti-hepatocellular carcinoma T-cells, BioLegend Ctla4 antibody (BioLegend, UC10-4B9) was used in flow cytometry on mouse samples (fig 3b). Immunol Cell Biol (2016) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 2
In order to investigate how Tregs are maintained in adipose tissue, BioLegend Ctla4 antibody (Biolegend, UC10-4B9) was used in flow cytometry on mouse samples (fig 2). Sci Rep (2015) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig s4
BioLegend Ctla4 antibody (biolegend, UC10-4B9) was used in flow cytometry on mouse samples (fig s4). Theranostics (2015) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 6
In order to optimize application routes for trifunctional bispecific antibodies against tumor-associated ganglioside GD2, BioLegend Ctla4 antibody (BioLegend, UC10-4B9) was used in flow cytometry on mouse samples (fig 6). Mol Cancer Ther (2015) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse
BioLegend Ctla4 antibody (BioLegend, UC10-4B9) was used in flow cytometry on mouse samples . Sci Rep (2015) ncbi
Syrian golden hamster monoclonal (9H10)
  • blocking or activating experiments; mouse; fig 3
BioLegend Ctla4 antibody (Biolegend, 9H10) was used in blocking or activating experiments on mouse samples (fig 3). Clin Exp Immunol (2015) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 5
In order to show that the PTEN-mTORC2 axis maintains T regulatory cell stability and coordinates their control of effector responses, BioLegend Ctla4 antibody (BioLegend, UC10-4B9) was used in flow cytometry on mouse samples (fig 5). Nat Immunol (2015) ncbi
Syrian golden hamster monoclonal (9H10)
  • flow cytometry; mouse
BioLegend Ctla4 antibody (BioLegend, 106210) was used in flow cytometry on mouse samples . J Immunol (2015) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse
BioLegend Ctla4 antibody (BioLegend, UC10-4B9) was used in flow cytometry on mouse samples . J Immunol (2014) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 2
BioLegend Ctla4 antibody (Biolegend, UC10-4B9) was used in flow cytometry on mouse samples (fig 2). PLoS ONE (2014) ncbi
Invitrogen
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig s7d
Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples (fig s7d). J Immunother Cancer (2021) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 1f
Invitrogen Ctla4 antibody (eBioscience, 12-1522-81) was used in flow cytometry on mouse samples (fig 1f). Adv Sci (Weinh) (2021) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; 1:100; loading ...
Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples at 1:100. Nat Commun (2021) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig s5b
Invitrogen Ctla4 antibody (eBioscience, 12-1522-82) was used in flow cytometry on mouse samples (fig s5b). Cell Rep (2020) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 1e
Invitrogen Ctla4 antibody (eBiosciences, UC10-4B9) was used in flow cytometry on mouse samples (fig 1e). J Exp Med (2019) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 2c
Invitrogen Ctla4 antibody (Thermo Fisher Scientific, 17-1522-82) was used in flow cytometry on mouse samples (fig 2c). J Clin Invest (2019) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 5c
Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples (fig 5c). J Exp Med (2018) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 3e
Invitrogen Ctla4 antibody (eBioscience, 121522) was used in flow cytometry on mouse samples (fig 3e). Br J Pharmacol (2018) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...
In order to characterize the regulatory T cells expressing T-bet transcriptional factor, Invitrogen Ctla4 antibody (eBioscience, 17-1522-82) was used in flow cytometry on mouse samples . Nature (2017) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 3a
Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples (fig 3a). Immunology (2017) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 4a
In order to generate and characterize Treg-of-B cells, Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples (fig 4a). Sci Rep (2017) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; 1:200; loading ...; fig 4c
In order to evaluate the use of a recombinant Newcastle disease virus expressing ICOS ligand to treat cancer, Invitrogen Ctla4 antibody (eBioscience, 12-1522) was used in flow cytometry on mouse samples at 1:200 (fig 4c). Nat Commun (2017) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 2e
Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples (fig 2e). Blood (2017) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 2b
In order to characterize conventional and regulatory T cells during pregnancy, Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples (fig 2b). Proc Natl Acad Sci U S A (2017) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...
In order to determine that NKG2C/E identifies the CD4 T cell effector subset ThCTL that develop in the lung during influenza A virus infection in mice, Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples . J Immunol (2017) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; human; 1:200; fig 1
  • flow cytometry; mouse; 1:200; fig 1
Invitrogen Ctla4 antibody (eBiosciences, 12-1522-82) was used in flow cytometry on human samples at 1:200 (fig 1) and in flow cytometry on mouse samples at 1:200 (fig 1). Nat Commun (2016) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig s3
In order to investigate osmostress-dependent and -independent functions of Nfat5 in T cells, Invitrogen Ctla4 antibody (eBiosciences, 17-1522-80) was used in flow cytometry on mouse samples (fig s3). Immunol Cell Biol (2017) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; loading ...; fig 5
In order to report the effects of PD-L1 modulation of T cell function in graft-versus-host disease, Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples (fig 5). J Clin Invest (2016) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 2
In order to establish that autophagy is essential for maintenance of a balanced CD4 positive intestinal T cell response, Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples (fig 2). elife (2016) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 5
Invitrogen Ctla4 antibody (eBioscience, 12-1522) was used in flow cytometry on mouse samples (fig 5). EMBO Mol Med (2015) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse
In order to report that GP96 is required for T regulatory cell maintenance and function, Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples . J Clin Invest (2015) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse
Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples . Sci Rep (2015) ncbi
Syrian golden hamster monoclonal (9H10)
  • blocking or activating experiments; mouse
Invitrogen Ctla4 antibody (eBioscience, 9H10) was used in blocking or activating experiments on mouse samples . J Immunol Methods (2014) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; human
Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on human samples . Cancer Res (2014) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse
In order to demonstrate that CTLA-4 promotes Tc17 differentiation and robust Tc17 responses, Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples . Eur J Immunol (2014) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse
In order to study the modulation of CD4 T-cell senescence and cytokine production and the roles played by Menin and Bach2, Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples . Nat Commun (2014) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse
Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples . J Immunol (2009) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse
In order to investigate crosstalk between that osteoclasts and T cells, Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples . J Immunol (2009) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse
In order to assess the role of T regulatory cells in Th2-type airway inflammation in mice, Invitrogen Ctla4 antibody (eBioscience, UC10-4B9) was used in flow cytometry on mouse samples . J Immunol (2008) ncbi
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; fig 1
In order to characterize and compare T helper 1 and 17 cells, Invitrogen Ctla4 antibody (eBiosciences, UC10-4B9) was used in flow cytometry on mouse samples (fig 1). J Leukoc Biol (2007) ncbi
hamsters monoclonal (1B8)
  • blocking or activating experiments; mouse; fig 1
In order to show that administration f antibodies that recognize CTLA-4 results in rejection of tumors, Invitrogen Ctla4 antibody (noco, noca) was used in blocking or activating experiments on mouse samples (fig 1). Science (1996) ncbi
Bio X Cell
mouse monoclonal (9D9)
  • blocking or activating experiments; mouse; fig s7a
Bio X Cell Ctla4 antibody (BioXCell, 9D9) was used in blocking or activating experiments on mouse samples (fig s7a). Nat Commun (2022) ncbi
mouse monoclonal (9D9)
  • blocking or activating experiments; mouse; ; fig 7h
Bio X Cell Ctla4 antibody (BioXCell, BE0164) was used in blocking or activating experiments on mouse samples at (fig 7h). Cell Rep (2021) ncbi
mouse monoclonal (9D9)
  • flow cytometry; mouse; 1:250; loading ...; fig 2c, 7a
Bio X Cell Ctla4 antibody (BioXcell, 9D9) was used in flow cytometry on mouse samples at 1:250 (fig 2c, 7a). Cancer Res (2021) ncbi
mouse monoclonal (9D9)
  • blocking or activating experiments; mouse; fig 1a
Bio X Cell Ctla4 antibody (BioXCell, 9D9) was used in blocking or activating experiments on mouse samples (fig 1a). BMC Biol (2020) ncbi
mouse monoclonal (9D9)
  • blocking or activating experiments; mouse; ; fig 4a
Bio X Cell Ctla4 antibody (Bioxcell, BE0164) was used in blocking or activating experiments on mouse samples at (fig 4a). Cell Res (2020) ncbi
Syrian golden hamster monoclonal (9H10)
  • immunohistochemistry; mouse; fig s5
Bio X Cell Ctla4 antibody (BioXcell, 9H10) was used in immunohistochemistry on mouse samples (fig s5). BMC Genomics (2020) ncbi
mouse monoclonal (9D9)
  • blocking or activating experiments; mouse; fig 2b
Bio X Cell Ctla4 antibody (BioXcell, 9D9) was used in blocking or activating experiments on mouse samples (fig 2b). JCI Insight (2018) ncbi
hamsters monoclonal (UC10-4F10-11)
  • blocking or activating experiments; mouse; loading ...; fig 4d
Bio X Cell Ctla4 antibody (Bio-X-cell, UC10-4F10-1) was used in blocking or activating experiments on mouse samples (fig 4d). J Immunol (2018) ncbi
Syrian golden hamster monoclonal (9H10)
  • blocking or activating experiments; mouse; loading ...; fig s2a
Bio X Cell Ctla4 antibody (BioXcell, 9H10) was used in blocking or activating experiments on mouse samples (fig s2a). Nat Commun (2017) ncbi
mouse monoclonal (9D9)
  • blocking or activating experiments; mouse
In order to demonstrate that type 1 T helper cells play a crucial role in vessel normalization, Bio X Cell Ctla4 antibody (BioXcell, 9D9) was used in blocking or activating experiments on mouse samples . Nature (2017) ncbi
hamsters monoclonal (UC10-4F10-11)
  • blocking or activating experiments; mouse; loading ...; fig 2a
Bio X Cell Ctla4 antibody (Bio X Cell, UC10-4F10-11) was used in blocking or activating experiments on mouse samples (fig 2a). elife (2015) ncbi
hamsters monoclonal (UC10-4F10-11)
  • blocking or activating experiments; mouse; fig 6
Bio X Cell Ctla4 antibody (BioxCell, UC10-4F10) was used in blocking or activating experiments on mouse samples (fig 6). J Clin Invest (2015) ncbi
Syrian golden hamster monoclonal (9H10)
  • blocking or activating experiments; mouse; loading ...; fig s3
In order to test if blocking several checkpoint receptors boosts anti-tumor immunity in a low-dose, lymphodepleting whole body radiation model, Bio X Cell Ctla4 antibody (BioXCell, 9H10) was used in blocking or activating experiments on mouse samples (fig s3). J Immunother Cancer (2015) ncbi
Santa Cruz Biotechnology
mouse monoclonal (F-8)
  • immunohistochemistry; mouse; 1:5000; loading ...; fig 7d
Santa Cruz Biotechnology Ctla4 antibody (Santa Cruz Biotechnology, sc-376016) was used in immunohistochemistry on mouse samples at 1:5000 (fig 7d). JCI Insight (2020) ncbi
mouse monoclonal (F-8)
  • flow cytometry; mouse; loading ...; fig 1b
Santa Cruz Biotechnology Ctla4 antibody (Santa Cruz, sc-376016) was used in flow cytometry on mouse samples (fig 1b). Braz J Med Biol Res (2016) ncbi
mouse monoclonal (F-8)
  • immunohistochemistry - paraffin section; human; 1:300; loading ...; fig 3c
Santa Cruz Biotechnology Ctla4 antibody (Santa Cruz, sc-376016) was used in immunohistochemistry - paraffin section on human samples at 1:300 (fig 3c). J Immunol Res (2016) ncbi
mouse monoclonal (F-8)
  • immunohistochemistry - paraffin section; human; 1:50; fig 2
Santa Cruz Biotechnology Ctla4 antibody (Santa Cruz, SC-376016) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 2). Breast Cancer Res (2016) ncbi
mouse monoclonal (F-8)
  • immunohistochemistry - paraffin section; human; 1:400; tbl 4
In order to test if atypical fibroxanthoma is the non-infiltrating precursor lesion of pleomorphic dermal sarcoma, Santa Cruz Biotechnology Ctla4 antibody (Santa Cruz, sc-376016) was used in immunohistochemistry - paraffin section on human samples at 1:400 (tbl 4). Oncotarget (2016) ncbi
Abcam
domestic rabbit monoclonal (CAL49)
  • immunohistochemistry; mouse; 1:500; loading ...
Abcam Ctla4 antibody (Abcam, CAL49) was used in immunohistochemistry on mouse samples at 1:500. NPJ Breast Cancer (2021) ncbi
monoclonal
  • flow cytometry; mouse; 1:200; fig 4c
In order to investigate the effects of caloric restriction on beige fat, Abcam Ctla4 antibody (Abcam, ab105155) was used in flow cytometry on mouse samples at 1:200 (fig 4c). Cell Metab (2016) ncbi
monoclonal
  • flow cytometry; mouse; 1:200
In order to elucidate how the microbiota-fat signaling axis affects beige-fat development, Abcam Ctla4 antibody (Abcam, ab105155) was used in flow cytometry on mouse samples at 1:200. Nat Med (2015) ncbi
Miltenyi Biotec
hamsters monoclonal (UC10-4B9)
  • flow cytometry; mouse; 1:20; fig 4a
Miltenyi Biotec Ctla4 antibody (Miltenyi, 130-102-570) was used in flow cytometry on mouse samples at 1:20 (fig 4a). Nat Commun (2019) ncbi
Tonbo Biosciences
monoclonal (UC104F1011)
  • flow cytometry; mouse; tbl s1
In order to study the role of ICOS in group 2 innate lymphoid cell responses, Tonbo Biosciences Ctla4 antibody (TONBO, UC10-4F10-11) was used in flow cytometry on mouse samples (tbl s1). Biochem Biophys Res Commun (2015) ncbi
BD Biosciences
hamsters monoclonal (UC10-4F10-11)
  • flow cytometry; mouse; loading ...; fig 1c
BD Biosciences Ctla4 antibody (BD, 553720) was used in flow cytometry on mouse samples (fig 1c). Nat Commun (2021) ncbi
hamsters monoclonal (UC10-4F10-11)
  • flow cytometry; mouse; 1:200; loading ...; fig s6-1e
BD Biosciences Ctla4 antibody (BD Biosciences, UC10-4F10-11) was used in flow cytometry on mouse samples at 1:200 (fig s6-1e). elife (2020) ncbi
hamsters monoclonal (UC10-4F10-11)
  • flow cytometry; mouse; loading ...
BD Biosciences Ctla4 antibody (BD Biosciences, clone UC10-4F10-11) was used in flow cytometry on mouse samples . elife (2020) ncbi
hamsters monoclonal (UC10-4F10-11)
  • flow cytometry; mouse; loading ...; fig 1g
BD Biosciences Ctla4 antibody (BD Biosciences, UC10-4F10-11) was used in flow cytometry on mouse samples (fig 1g). J Clin Invest (2019) ncbi
hamsters monoclonal (UC10-4F10-11)
  • flow cytometry; mouse; loading ...; fig 3c, 4f
BD Biosciences Ctla4 antibody (BD, UC10-4F10-11) was used in flow cytometry on mouse samples (fig 3c, 4f). Proc Natl Acad Sci U S A (2018) ncbi
hamsters monoclonal (UC10-4F10-11)
  • flow cytometry; mouse; fig s2a
BD Biosciences Ctla4 antibody (Becton Dickinson, UC10-4F10-11) was used in flow cytometry on mouse samples (fig s2a). Immunity (2017) ncbi
hamsters monoclonal (UC10-4F10-11)
  • blocking or activating experiments; mouse; loading ...; fig 2a
BD Biosciences Ctla4 antibody (BD Biosciences, UC10-4F10) was used in blocking or activating experiments on mouse samples (fig 2a). Cell Death Differ (2017) ncbi
hamsters monoclonal (UC10-4F10-11)
  • flow cytometry; mouse; loading ...
In order to explore the contribution of IL-33 in a model of rheumatoid arthritis, BD Biosciences Ctla4 antibody (BD Biosciences, UC10-4F10-11) was used in flow cytometry on mouse samples . J Immunol (2016) ncbi
hamsters monoclonal (UC10-4F10-11)
  • flow cytometry; mouse; loading ...; fig s1a
In order to ask if T-bet regulates other T regulatory cell functions after entering the inflammatory site, BD Biosciences Ctla4 antibody (BD PharMingen, UC10-4F10-11) was used in flow cytometry on mouse samples (fig s1a). J Immunol (2016) ncbi
hamsters monoclonal (UC10-4F10-11)
  • flow cytometry; mouse; 1:200
BD Biosciences Ctla4 antibody (BD Bioscience, UC10-4F10-11) was used in flow cytometry on mouse samples at 1:200. J Endod (2016) ncbi
hamsters monoclonal (UC10-4F10-11)
  • immunocytochemistry; mouse
In order to examine the role of the immunological synapse in T cell activation, BD Biosciences Ctla4 antibody (BD, UC10-4F10-11) was used in immunocytochemistry on mouse samples . Immunol Cell Biol (2015) ncbi
hamsters monoclonal (UC10-4F10-11)
  • flow cytometry; mouse
In order to study the role of CD93 molecule in mature dendritic cells and T cells, BD Biosciences Ctla4 antibody (BD Biosciences, UC10-4F10-11) was used in flow cytometry on mouse samples . Immunobiology (2015) ncbi
Articles Reviewed
  1. Que W, Ma K, Hu X, Guo W, Li X. Combinations of anti-GITR antibody and CD28 superagonist induce permanent allograft acceptance by generating type 1 regulatory T cells. Sci Adv. 2022;8:eabo4413 pubmed publisher
  2. Lu L, Li T, Feng X, Liu Z, Liu Y, Chao T, et al. Excessive immunosuppression by regulatory T cells antagonizes T cell response to schistosome infection in PD-1-deficient mice. PLoS Pathog. 2022;18:e1010596 pubmed publisher
  3. Saxena V, Piao W, Li L, Paluskievicz C, Xiong Y, Simon T, et al. Treg tissue stability depends on lymphotoxin beta-receptor- and adenosine-receptor-driven lymphatic endothelial cell responses. Cell Rep. 2022;39:110727 pubmed publisher
  4. Wedge M, Jennings V, Crupi M, Poutou J, Jamieson T, Pelin A, et al. Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy. Nat Commun. 2022;13:1898 pubmed publisher
  5. Liu H, Pedros C, Kong K, Canonigo Balancio A, Xue W, Altman A. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy. J Immunother Cancer. 2021;9: pubmed publisher
  6. Rizvi Z, Dalal R, Sadhu S, Kumar Y, Kumar S, Gupta S, et al. High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity. Sci Adv. 2021;7:eabg5016 pubmed publisher
  7. Wang Z, He L, Li W, Xu C, Zhang J, Wang D, et al. GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma. J Immunother Cancer. 2021;9: pubmed publisher
  8. Kim G, Kim W, Lim S, Lee H, Koo J, Nam K, et al. In Vivo Induction of Regulatory T Cells Via CTLA-4 Signaling Peptide to Control Autoimmune Encephalomyelitis and Prevent Disease Relapse. Adv Sci (Weinh). 2021;8:2004973 pubmed publisher
  9. Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, et al. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Rep. 2021;36:109412 pubmed publisher
  10. Amoozgar Z, Kloepper J, Ren J, Tay R, Kazer S, Kiner E, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021;12:2582 pubmed publisher
  11. Steenbrugge J, Vander Elst N, Demeyere K, De Wever O, Sanders N, van den Broeck W, et al. OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer. NPJ Breast Cancer. 2021;7:27 pubmed publisher
  12. Yang Y, Li X, Ma Z, Wang C, Yang Q, Byrne Steele M, et al. CTLA-4 expression by B-1a B cells is essential for immune tolerance. Nat Commun. 2021;12:525 pubmed publisher
  13. Kharkwal S, Johndrow C, Veerapen N, Kharkwal H, Saavedra Avila N, Carreño L, et al. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy. Cancer Res. 2021;81:1788-1801 pubmed publisher
  14. Rundqvist H, Veliça P, Barbieri L, Gameiro P, Bargiela D, Gojkovic M, et al. Cytotoxic T-cells mediate exercise-induced reductions in tumor growth. elife. 2020;9: pubmed publisher
  15. Pasciuto E, Burton O, Roca C, Lagou V, Rajan W, Theys T, et al. Microglia Require CD4 T Cells to Complete the Fetal-to-Adult Transition. Cell. 2020;182:625-640.e24 pubmed publisher
  16. Li H, Lu C, Zhang H, Hu Q, Zhang J, Cuevas I, et al. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight. 2020;5: pubmed publisher
  17. Gryzik S, Hoang Y, Lischke T, Mohr E, Venzke M, Kadner I, et al. Identification of a super-functional Tfh-like subpopulation in murine lupus by pattern perception. elife. 2020;9: pubmed publisher
  18. Ruscetti M, Morris J, Mezzadra R, Russell J, Leibold J, Romesser P, et al. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell. 2020;181:424-441.e21 pubmed publisher
  19. Zhang S, Liang W, Luo L, Sun S, Wang F. The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology. BMC Biol. 2020;18:29 pubmed publisher
  20. Hu X, Deng Q, Ma L, Li Q, Chen Y, Liao Y, et al. Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res. 2020;30:229-243 pubmed publisher
  21. Cohen G, Chandran P, Lorsung R, Tomlinson L, Sundby M, Burks S, et al. The Impact of Focused Ultrasound in Two Tumor Models: Temporal Alterations in the Natural History on Tumor Microenvironment and Immune Cell Response. Cancers (Basel). 2020;12: pubmed publisher
  22. Canel M, Taggart D, Sims A, Lonergan D, Waizenegger I, Serrels A. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. elife. 2020;9: pubmed publisher
  23. Blagih J, Zani F, Chakravarty P, Hennequart M, Pilley S, Hobor S, et al. Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Rep. 2020;30:481-496.e6 pubmed publisher
  24. Zhong W, Myers J, Wang F, Wang K, Lucas J, Rosfjord E, et al. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. BMC Genomics. 2020;21:2 pubmed publisher
  25. Wang L, Shen E, Luo L, Rabe H, Wang Q, Yin J, et al. Control of Germinal Center Localization and Lineage Stability of Follicular Regulatory T Cells by the Blimp1 Transcription Factor. Cell Rep. 2019;29:1848-1861.e6 pubmed publisher
  26. Benci J, Johnson L, Choa R, Xu Y, Qiu J, Zhou Z, et al. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell. 2019;178:933-948.e14 pubmed publisher
  27. Leclerc M, Voilin E, Gros G, Corgnac S, de Montpreville V, Validire P, et al. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun. 2019;10:3345 pubmed publisher
  28. Papaioannou E, Yanez D, Ross S, Lau C, Solanki A, Chawda M, et al. Sonic Hedgehog signaling limits atopic dermatitis via Gli2-driven immune regulation. J Clin Invest. 2019;129:3153-3170 pubmed publisher
  29. Di Pilato M, Kim E, Cadilha B, Prüßmann J, Nasrallah M, Seruggia D, et al. Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. Nature. 2019;570:112-116 pubmed publisher
  30. Sugiura D, Maruhashi T, Okazaki I, Shimizu K, Maeda T, Takemoto T, et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science. 2019;364:558-566 pubmed publisher
  31. Visekruna A, Hartmann S, Sillke Y, Glauben R, Fischer F, Raifer H, et al. Intestinal development and homeostasis require activation and apoptosis of diet-reactive T cells. J Clin Invest. 2019;129:1972-1983 pubmed publisher
  32. Xing S, Gai K, Li X, Shao P, Zeng Z, Zhao X, et al. Tcf1 and Lef1 are required for the immunosuppressive function of regulatory T cells. J Exp Med. 2019;: pubmed publisher
  33. Michaels Y, Barnkob M, Barbosa H, Baeumler T, Thompson M, Andre V, et al. Precise tuning of gene expression levels in mammalian cells. Nat Commun. 2019;10:818 pubmed publisher
  34. Anandagoda N, Willis J, Hertweck A, Roberts L, Jackson I, Gökmen M, et al. microRNA-142-mediated repression of phosphodiesterase 3B critically regulates peripheral immune tolerance. J Clin Invest. 2019;129:1257-1271 pubmed publisher
  35. Sato Y, Bolzenius J, Eteleeb A, Su X, Maher C, Sehn J, et al. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. JCI Insight. 2018;3: pubmed publisher
  36. Atretkhany K, Mufazalov I, Dunst J, Kuchmiy A, Gogoleva V, Andruszewski D, et al. Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity. Proc Natl Acad Sci U S A. 2018;115:13051-13056 pubmed publisher
  37. Alissafi T, Hatzioannou A, Mintzas K, Barouni R, Banos A, Sormendi S, et al. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells. J Clin Invest. 2018;128:3840-3852 pubmed publisher
  38. Emmerson A, Trevelin S, Mongue Din H, Becker P, Ortiz C, Smyth L, et al. Nox2 in regulatory T cells promotes angiotensin II-induced cardiovascular remodeling. J Clin Invest. 2018;128:3088-3101 pubmed publisher
  39. Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells. J Exp Med. 2018;215:985-997 pubmed publisher
  40. Lu Y, Kim N, Jiang Y, Zhang H, Zheng D, Zhu F, et al. Cambogin suppresses dextran sulphate sodium-induced colitis by enhancing Treg cell stability and function. Br J Pharmacol. 2018;175:1085-1099 pubmed publisher
  41. Shi B, Geng J, Wang Y, Wei H, Walters B, Li W, et al. Foxp1 Negatively Regulates T Follicular Helper Cell Differentiation and Germinal Center Responses by Controlling Cell Migration and CTLA-4. J Immunol. 2018;200:586-594 pubmed publisher
  42. Kishore M, Cheung K, Fu H, Bonacina F, Wang G, Coe D, et al. Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. Immunity. 2017;47:875-889.e10 pubmed publisher
  43. Singh M, Vianden C, Cantwell M, Dai Z, Xiao Z, Sharma M, et al. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017;8:1447 pubmed publisher
  44. Lingel H, Wissing J, Arra A, Schanze D, Lienenklaus S, Klawonn F, et al. CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation. Cell Death Differ. 2017;24:1739-1749 pubmed publisher
  45. Levine A, Mendoza A, Hemmers S, Moltedo B, Niec R, Schizas M, et al. Stability and function of regulatory T cells expressing the transcription factor T-bet. Nature. 2017;546:421-425 pubmed publisher
  46. Meinicke H, Bremser A, Brack M, Akeus P, Pearson C, Bullers S, et al. Tumour-associated changes in intestinal epithelial cells cause local accumulation of KLRG1+ GATA3+ regulatory T cells in mice. Immunology. 2017;152:74-88 pubmed publisher
  47. Chien C, Yu H, Chen S, Chiang B. Characterization of c-Maf+Foxp3- Regulatory T Cells Induced by Repeated Stimulation of Antigen-Presenting B Cells. Sci Rep. 2017;7:46348 pubmed publisher
  48. Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544:250-254 pubmed publisher
  49. Liu Z, Ravindranathan R, Kalinski P, Guo Z, Bartlett D. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8:14754 pubmed publisher
  50. Zamarin D, Holmgaard R, Ricca J, Plitt T, Palese P, Sharma P, et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017;8:14340 pubmed publisher
  51. Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017;129:2186-2197 pubmed publisher
  52. Engler J, Kursawe N, Solano M, Patas K, Wehrmann S, Heckmann N, et al. Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy. Proc Natl Acad Sci U S A. 2017;114:E181-E190 pubmed publisher
  53. Marshall N, Vong A, Devarajan P, Brauner M, Kuang Y, Nayar R, et al. NKG2C/E Marks the Unique Cytotoxic CD4 T Cell Subset, ThCTL, Generated by Influenza Infection. J Immunol. 2017;198:1142-1155 pubmed publisher
  54. Mai T, Ma R, Li Z, Bi S. Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer. Braz J Med Biol Res. 2016;49:e5620 pubmed publisher
  55. Kaewkangsadan V, Verma C, Eremin J, Cowley G, Ilyas M, Eremin O. Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. J Immunol Res. 2016;2016:4757405 pubmed
  56. Fabbiano S, Suárez Zamorano N, Rigo D, Veyrat Durebex C, Stevanovic Dokic A, Colin D, et al. Caloric Restriction Leads to Browning of White Adipose Tissue through Type 2 Immune Signaling. Cell Metab. 2016;24:434-446 pubmed publisher
  57. Shi L, Fu T, Guan B, Chen J, Blando J, Allison J, et al. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined ?-CTLA-4+?-PD-1 therapy. Nat Commun. 2016;7:12335 pubmed publisher
  58. Yoshioka D, Kajiwara C, Ishii Y, Umeki K, Hiramatsu K, Kadota J, et al. Efficacy of ?-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal Pneumonia. Antimicrob Agents Chemother. 2016;60:6146-54 pubmed publisher
  59. Alberdi M, Iglesias M, Tejedor S, Merino R, Lopez Rodriguez C, Aramburu J. Context-dependent regulation of Th17-associated genes and IFN? expression by the transcription factor NFAT5. Immunol Cell Biol. 2017;95:56-67 pubmed publisher
  60. Kritikou J, Dahlberg C, Baptista M, Wagner A, Banerjee P, Gwalani L, et al. IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo. Sci Rep. 2016;6:30636 pubmed publisher
  61. Biton J, Khaleghparast Athari S, Thiolat A, Santinon F, Lemeiter D, Hervé R, et al. In Vivo Expansion of Activated Foxp3+ Regulatory T Cells and Establishment of a Type 2 Immune Response upon IL-33 Treatment Protect against Experimental Arthritis. J Immunol. 2016;197:1708-19 pubmed publisher
  62. Saha A, O Connor R, Thangavelu G, Lovitch S, Dandamudi D, Wilson C, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126:2642-60 pubmed publisher
  63. Duchnowska R, Pęksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, et al. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res. 2016;18:43 pubmed publisher
  64. Seidel P, Remus M, Delacher M, Grigaravicius P, Reuss D, Frappart L, et al. Epidermal Nbn deletion causes premature hair loss and a phenotype resembling psoriasiform dermatitis. Oncotarget. 2016;7:23006-18 pubmed publisher
  65. Apostolidis S, Rodríguez Rodríguez N, Suárez Fueyo A, Dioufa N, Ozcan E, Crispín J, et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nat Immunol. 2016;17:556-64 pubmed publisher
  66. Helbig D, Ihle M, Pütz K, Tantcheva Poor I, Mauch C, Büttner R, et al. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget. 2016;7:21763-74 pubmed publisher
  67. Kabat A, Harrison O, Riffelmacher T, Moghaddam A, Pearson C, Laing A, et al. The autophagy gene Atg16l1 differentially regulates Treg and TH2 cells to control intestinal inflammation. elife. 2016;5:e12444 pubmed publisher
  68. Xiong Y, Ahmad S, Iwami D, Brinkman C, Bromberg J. T-bet Regulates Natural Regulatory T Cell Afferent Lymphatic Migration and Suppressive Function. J Immunol. 2016;196:2526-40 pubmed publisher
  69. Wei R, Hu Y, Dong F, Xu X, Hu A, Gao G. Hepatoma cell-derived leptin downregulates the immunosuppressive function of regulatory T-cells to enhance the anti-tumor activity of CD8+ T-cells. Immunol Cell Biol. 2016;94:388-99 pubmed publisher
  70. Francisconi C, Vieira A, Biguetti C, Glowacki A, Trombone A, Letra A, et al. Characterization of the Protective Role of Regulatory T Cells in Experimental Periapical Lesion Development and Their Chemoattraction Manipulation as a Therapeutic Tool. J Endod. 2016;42:120-6 pubmed publisher
  71. Onodera T, Fukuhara A, Jang M, Shin J, Aoi K, Kikuta J, et al. Adipose tissue macrophages induce PPARγ-high FOXP3(+) regulatory T cells. Sci Rep. 2015;5:16801 pubmed publisher
  72. Suárez Zamorano N, Fabbiano S, Chevalier C, Stojanović O, Colin D, Stevanović A, et al. Microbiota depletion promotes browning of white adipose tissue and reduces obesity. Nat Med. 2015;21:1497-1501 pubmed publisher
  73. Kim J, Phan T, Nguyen V, Dinh Vu H, Zheng J, Yun M, et al. Salmonella typhimurium Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1β. Theranostics. 2015;5:1328-42 pubmed publisher
  74. Welten S, Redeker A, Franken K, Oduro J, Ossendorp F, Čičin Šain L, et al. The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion. elife. 2015;4: pubmed publisher
  75. Deppisch N, Ruf P, Eissler N, Neff F, Buhmann R, Lindhofer H, et al. Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery. Mol Cancer Ther. 2015;14:1877-83 pubmed publisher
  76. Kamachi F, Isshiki T, Harada N, Akiba H, Miyake S. ICOS promotes group 2 innate lymphoid cell activation in lungs. Biochem Biophys Res Commun. 2015;463:739-45 pubmed publisher
  77. Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow S, Yong M, et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest. 2015;125:2077-89 pubmed publisher
  78. Li C, Li W, Xiao J, Jiao S, Teng F, Xue S, et al. ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. EMBO Mol Med. 2015;7:754-69 pubmed publisher
  79. Jing W, Gershan J, Weber J, Tlomak D, McOlash L, Sabatos Peyton C, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer. 2015;3:2 pubmed publisher
  80. Zhang Y, Wu B, Metelli A, Thaxton J, Hong F, Rachidi S, et al. GP96 is a GARP chaperone and controls regulatory T cell functions. J Clin Invest. 2015;125:859-69 pubmed publisher
  81. Glatigny S, Duhen R, Arbelaez C, Kumari S, Bettelli E. Integrin alpha L controls the homing of regulatory T cells during CNS autoimmunity in the absence of integrin alpha 4. Sci Rep. 2015;5:7834 pubmed publisher
  82. Singh K, Hjort M, Thorvaldson L, Sandler S. Concomitant analysis of Helios and Neuropilin-1 as a marker to detect thymic derived regulatory T cells in naïve mice. Sci Rep. 2015;5:7767 pubmed publisher
  83. Chu K, Chiang B. Characterization and functional studies of forkhead box protein 3(-) lymphocyte activation gene 3(+) CD4(+) regulatory T cells induced by mucosal B cells. Clin Exp Immunol. 2015;180:316-28 pubmed publisher
  84. Shrestha S, Yang K, Guy C, Vogel P, Neale G, Chi H. Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat Immunol. 2015;16:178-87 pubmed publisher
  85. Naik A, Hawwari A, Krangel M. Specification of Vδ and Vα usage by Tcra/Tcrd locus V gene segment promoters. J Immunol. 2015;194:790-4 pubmed publisher
  86. Thauland T, Koguchi Y, Dustin M, Parker D. CD28-CD80 interactions control regulatory T cell motility and immunological synapse formation. J Immunol. 2014;193:5894-903 pubmed publisher
  87. Lin W, Fan Z, Suo Y, Deng Y, Zhang M, Wang J, et al. The bullseye synapse formed between CD4+ T-cell and staphylococcal enterotoxin B-pulsed dendritic cell is a suppressive synapse in T-cell response. Immunol Cell Biol. 2015;93:99-110 pubmed publisher
  88. Kreiser S, Eckhardt J, Kuhnt C, Stein M, Krzyzak L, Seitz C, et al. Murine CD83-positive T cells mediate suppressor functions in vitro and in vivo. Immunobiology. 2015;220:270-9 pubmed publisher
  89. Verhagen J, Wraith D. Blockade of LFA-1 augments in vitro differentiation of antigen-induced Foxp3? Treg cells. J Immunol Methods. 2014;414:58-64 pubmed publisher
  90. Zhu Y, Knolhoff B, Meyer M, Nywening T, West B, Luo J, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74:5057-69 pubmed publisher
  91. Berod L, Stüve P, Varela F, Behrends J, Swallow M, Kruse F, et al. Rapid rebound of the Treg compartment in DEREG mice limits the impact of Treg depletion on mycobacterial burden, but prevents autoimmunity. PLoS ONE. 2014;9:e102804 pubmed publisher
  92. Pick J, Arra A, Lingel H, Hegel J, Huber M, Nishanth G, et al. CTLA-4 (CD152) enhances the Tc17 differentiation program. Eur J Immunol. 2014;44:2139-52 pubmed publisher
  93. Kuwahara M, Suzuki J, Tofukuji S, Yamada T, Kanoh M, Matsumoto A, et al. The Menin-Bach2 axis is critical for regulating CD4 T-cell senescence and cytokine homeostasis. Nat Commun. 2014;5:3555 pubmed publisher
  94. Blache C, Adriouch S, Calbo S, Drouot L, Dulauroy S, Arnoult C, et al. Cutting edge: CD4-independent development of functional FoxP3+ regulatory T cells. J Immunol. 2009;183:4182-6 pubmed publisher
  95. Kiesel J, Buchwald Z, Aurora R. Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. J Immunol. 2009;182:5477-87 pubmed publisher
  96. Saito K, Torii M, Ma N, Tsuchiya T, Wang L, Hori T, et al. Differential regulatory function of resting and preactivated allergen-specific CD4+ CD25+ regulatory T cells in Th2-type airway inflammation. J Immunol. 2008;181:6889-97 pubmed
  97. Nakae S, Iwakura Y, Suto H, Galli S. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol. 2007;81:1258-68 pubmed
  98. Leach D, Krummel M, Allison J. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734-6 pubmed